Design and Development of Fast Dissolving Tablet of Gliclazide

sharad Kondiba Kamble, S. ShindeSunita
{"title":"Design and Development of Fast Dissolving Tablet of Gliclazide","authors":"sharad Kondiba Kamble, S. ShindeSunita","doi":"10.4172/2329-6631.1000177","DOIUrl":null,"url":null,"abstract":"In the present study, Gliclazide is a second-generation sulfonyl urea derivative used to treat non-insulin dependent diabetes mellitus. The drug has been classified as class-II drug according to biopharmaceutical classification system having low solubility and high permeability. So, an attempt was made to enhance the solubility of gliclazide by solvent evaporation technique. A significant enhancement of gliclazide dissolution rate will be obtained using by using suitable techniques. In this PVP-k30, polyethylene glycol and soluplus were mixed with the drug in different ratios (1:1, 1:3) and prepare P1, P2, PE1, PE2, S1 and S2 solid dispersion batches. The optimized solid dispersions P1 were further kneaded with suitable proportions of super disintegrants such as; Cross carmellose and Sodium starch glycolate. Dissolution profile will show decrease amount of drug release at specified time. DSC as well as X-ray diffraction showed reduced drug crystallinity in SDs. Scanning electron microscopy and particle size analysis revealed significant decreased particle size of the drug in SDs. FT-IR spectroscopy demonstrated no detectable interactions between the drug and excipients. On that the P1 batch will be consider for eight different fast dissolving tablets Preparation. The prepared FDT’s were evaluated for various parameters like disintegration time, wetting time, drug content, in vitro drug release study etc. and shows the satisfactory result. The formulation of F-4 containing cross carmellose sodium (5%) showed better result in disintegration time 11 sec. and maximum in vitro drug release of 99.89% at the end of 40 minutes.","PeriodicalId":15589,"journal":{"name":"Journal of Developing Drugs","volume":"48 1","pages":"1-13"},"PeriodicalIF":0.0000,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"6","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Developing Drugs","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4172/2329-6631.1000177","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 6

Abstract

In the present study, Gliclazide is a second-generation sulfonyl urea derivative used to treat non-insulin dependent diabetes mellitus. The drug has been classified as class-II drug according to biopharmaceutical classification system having low solubility and high permeability. So, an attempt was made to enhance the solubility of gliclazide by solvent evaporation technique. A significant enhancement of gliclazide dissolution rate will be obtained using by using suitable techniques. In this PVP-k30, polyethylene glycol and soluplus were mixed with the drug in different ratios (1:1, 1:3) and prepare P1, P2, PE1, PE2, S1 and S2 solid dispersion batches. The optimized solid dispersions P1 were further kneaded with suitable proportions of super disintegrants such as; Cross carmellose and Sodium starch glycolate. Dissolution profile will show decrease amount of drug release at specified time. DSC as well as X-ray diffraction showed reduced drug crystallinity in SDs. Scanning electron microscopy and particle size analysis revealed significant decreased particle size of the drug in SDs. FT-IR spectroscopy demonstrated no detectable interactions between the drug and excipients. On that the P1 batch will be consider for eight different fast dissolving tablets Preparation. The prepared FDT’s were evaluated for various parameters like disintegration time, wetting time, drug content, in vitro drug release study etc. and shows the satisfactory result. The formulation of F-4 containing cross carmellose sodium (5%) showed better result in disintegration time 11 sec. and maximum in vitro drug release of 99.89% at the end of 40 minutes.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
格列齐特速溶片的设计与研制
在本研究中,格列齐特是第二代磺酰脲衍生物,用于治疗非胰岛素依赖型糖尿病。根据生物制药分类系统,该药物具有低溶解度和高渗透性,被归类为ii类药物。为此,尝试采用溶剂蒸发技术提高格列齐特的溶解度。采用合适的工艺可显著提高格列齐特的溶出率。在PVP-k30中,将聚乙二醇和溶液按不同比例(1:1,1:3)与药物混合,制备P1, P2, PE1, PE2, S1和S2固体分散批。将优化后的固体分散体P1与合适比例的强力崩解剂(如;交叉carmellose和Sodium starch glycolate。溶出曲线显示在一定时间内药物释放量减少。DSC和x射线衍射显示SDs中的药物结晶度降低。扫描电镜和粒径分析显示SDs中药物粒径明显减小。傅里叶变换红外光谱显示没有检测到药物和辅料之间的相互作用。在此基础上,P1批将被考虑用于八种不同的快速溶解片剂制备。对制备的FDT进行了崩解时间、润湿时间、药物含量、体外释药研究等参数的评价,取得了满意的结果。以5%交叉卡梅糖钠为主要成分的F-4为最佳处方,崩解时间为11秒,崩解40 min时体外最大释药率为99.89%。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Fast Dissolving Tablets: A Comfortable Dosage Form for Geriatrics,Pediatrics, Bed Ridden Patients Is Vitamin D more Important than the Medicine? A Short Note Acknowledgment on Developing Drugs The Efficacy of Treating Pulmonary Fibrosis and Pulmonary Function Injury in COVID-19 with Fuzheng Huayu Tablets: Study Protocol for a Multicenter Randomized Controlled Trial Formulation of Oral films for the Treatment of Cough
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1